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ABSTRACT
We studied 30 pediatric patients with malignant (n 16) or nonmalignant (n 14) conditions. The preparative
regimen consisted of fludarabine, intravenous (IV) busulfan (Bu) for 2 daily doses, and antithymocyte globulin
before stem cell transplantation. A test dose of IV Bu (0.8 mg/kg), anticipated to target an area under the
concentration-time curve (AUC) of 800 to 1200 mol · min, was followed later by 2 daily doses adjusted
according to the pharmacokinetics (PK) to target an AUC of 3200 to 4800 mol · min. The median test dose
AUC was 953 mol · min (range, 439-1315 mol · min). The median AUC of single daily doses was 3798
mol · min (range, 1511-7254 mol · min). PK-based dose modification was required in 20 patients: 12 were
adjusted to a higher dose, and in 8 the dose was decreased. Nausea and vomiting were noted in 15 patients. No
patient developed hepatic veno-occlusive disease or seizures. Full donor chimerism was attained in 20 patients
(mean of 24.5 days), 3 achieved partial chimerism, 5 did not engraft, and in 2 it is too early to assess chimerism.
Acute graft-versus-host disease developed in 11 patients, grades I to II developed in 10 patients, and grade III
developed in 1. Four patients died of infection and 5 of progressive disease. Thus, PK of a test dose of IV Bu
provided information to adjust subsequent daily doses of IV Bu: this resulted in a regimen that was feasible,
safe, and convenient for administration to children.
© 2006 American Society for Blood and Marrow Transplantation
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TNTRODUCTION
The reproducible pharmacokinetic (PK) proﬁle of
ntravenously (IV) administered busulfan (Bu) in adult
atients undergoing stem cell transplantation (SCT) is
n marked contrast to the erratic and unpredictable
K values noted with oral Bu in pediatric patients
1-3]. The erratic intestinal absorption of oral Bu and
he variable clearance in pediatric patients contributes
o wide intrapatient variability in area under the con-
entration-time curve (AUC) measurements [4,5]. a
72ith the use of the IV preparation, it is thought that
his problem will be resolved. To evaluate the use of
V Bu in pediatric patients receiving single daily doses,
e undertook a clinical trial to assess the PK of single
aily doses in pediatric patients. We hypothesized that
test dose of IV Bu PK before transplantation allows
or a strategy that could better predict a particular Bu
arget AUC in a patient receiving a single daily dose.
he test dose of IV Bu could also result in less toxicity
nd better Bu exposure. There are no previously re-
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Single Daily-Dose Intravenous Busulfan in Pediatric Transplant Patients
Borted clinical studies with single daily-dose IV Bu in
hildren undergoing hematopoietic SCT (HSCT).
Most experience with the IV formulation of Bu
as been with the traditional 4-times-daily dosing (16
oses) [6,7]. However, daily dosing and twice-daily
osing of IV Bu with a test dose have been found to be
afe with reproducible PKs in patients with hemato-
ogic malignant diseases undergoing HSCT [8]. The
ollection of 4 or 5 samples after the ﬁrst test dose was
alidated by demonstrating reproducible PK [8]. This
nding conﬁrms previous sampling strategies for
harmacokinetically directed dosing with high-dose
V Bu in HSCT preparative regimens [9]. It seems
hat a single daily dose of IV Bu  4 days combined
ith cyclophosphamide can be used as a pretransplan-
ation conditioning regimen for patients with ad-
anced hematologic malignant disease [8].
The results of a recent study [10] demonstrated
hat a conditioning regimen of once-daily IV Bu 3.2
g/kg for 4 days and ﬂudarabine (Flu) 50 mg/m2 for
days was relatively well tolerated and showed pre-
ictable Bu blood concentrations in 15- to 64-year-old
atients undergoing allogeneic HSCT. Earlier trials
ith conditioning regimens used IV Bu in combina-
able 1. Patient Characteristics
Patient
No.
Type of
Donor
Degree of
Matching Age (y)
1 UCB 2-antigen mismatch .5 SCID (
2 UCB 2-antigen mismatch 6 Neutro
3 MUD 10/10 16 ALL
4 MUD 9/10 8 CML
5 MUD 10/10 10 Infant
6 MUD 3.5 Aplast
7 UCB 2-antigen mismatch .5 Infant
8 MUD 1-antigen mismatch 8 ANLL
9 MUD 9/10 6 Neuro
10 MUD 10/10 9 ALL
11 MUD 9/10 13 CML
12 MS 10/10 6 Neuro
13 MUD 10/10 10 ALL
14 MS 10/10 8 Hyper
15 PMR 8/10 .4 Gauch
16 MUD 9/10 13 Rhabd
17 UCB 1-antigen mismatch .1 SCID
18 MUD 10/10 9 NHL i
19 UCB 2-antigen mismatch .4 SCID
20 MS 10/10 10 ALL C
21 MUD 10/10 10 X-linke
22 MS 10/10 14 NHL
23 UCB 2-antigen mismatch .7 SCID
24 MS 10/10 15 CML
25 MUD 9/10 1 Wisko
26 UCB 1-antigen mismatch .4 SCID
27 UCB 1-antigen mismatch .1 Krabbe
28 MUD 10/10 12 Kostm
29 MUD 10/10 1 Famili
lymp
30 MS 10/10 16 Aplast
CB indicates unrelated umbilical cord blood; MUD, matched unre
severe combined immunodeﬁciency; ANLL, acute nonlympho
NHL, non-Hodgkin lymphoma; CR, complete remission; PR, partial
B&MTion with cyclophosphamide because these myeloab-
ative drugs were found to be successful in engrafting
ransplantation patients [6,11]. In these studies, IV Bu
as administered 4 times daily for 4 days and pro-
uced predictable and consistent PK proﬁles along
ith acceptable toxicity [11].
In this study, a complete PK proﬁle of a single daily
ose of IV Buwas determined, along with the assessment
f the value of the test dose to adjust the single daily dose
o obtain an optimal AUC. The toxicity and engraftment
f this combination regimen after transplantation were
lso assessed.
ATIENTS AND METHODS
Thirty consecutive pediatric patients with high-
isk malignancies (n  16) or non malignant (n  14)
onditions who were part of a reduced-intensity con-
itioning regimen (RIC) protocol underwent alloge-
eic HSCT with a single daily-dose IV Bu regimen at
hildren’s Memorial Hospital from July 2003 to Sep-
ember 2005. Patient characteristics are summarized
n Table 1. All patients were required to have their
Diagnosis Status of Disease at Transplantation
n) Active disease
ma stage IV PR2
CR2
Molecular relapse
CR1
ia Unresponsive to immune therapy
ia CR1
CR2
a stage IV Persistent marrow disease
CR3
Chronic 2
a stage IV Relapse
CR2
ndrome Active disease
2 Active disease
rcoma/MDS Active disease
Active disease
CR2
Active disease
CR2
hoproliferative disease Active disease
Active disease
Active disease
Chronic phase
ich Active disease
Active disease
se Active disease
Active disease
ophagocytic
iocytosis
Active disease
ia Aplasia
onor; MS, matched sibling; PMR, partially matched related; SCID,
eukemia; Ig, immunoglobulin; MDS, myelodysplastic syndrome;Omen
blasto
ALL
ic anem
leukem
blastom
blastom
IgM sy
er type
omyosa
n CR2
R2
d lymp
tt-Aldr
disea
ann
al hem
hohist
ic anem
lated d
cytic lresponse.
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4iagnosis conﬁrmed by histological or laboratory test-
ng. Signed informed consent by parents and assent of
he patient (when applicable) to participate in the
rotocol and have their records used for research were
btained in compliance with the hospital’s institu-
ional review board.
reatment Regimen
Patients were enrolled on an RIC transplant pro-
ocol developed at Children’s Memorial Hospital
12,13]. The regimen included a single test dose (0.8
g/kg) of IV Bu given over 2 hours on day 10, Flu
0 mg/m2 on days 10 to 5, IV Bu 3.2 mg/kg/d on
ays 5 and 4 (as a 3-hour infusion with modiﬁca-
ions of the dose based on the result of the test dose
K), and rabbit antithymocyte globulin (ATG) 2 mg/
g/d or equine ATG 40 mg/kg/d on days4,3,2,
nd 1. Allogeneic hematopoietic stem cells were
nfused on day 0.
To optimize engraftment and minimize toxicities,
t has become standard practice with regimens using
6 doses (IV or oral) to determine the PK of the ﬁrst
ose and adjust the remaining dosages. Because our
egimen uses only 2 single daily doses of Bu, PK
nalysis of the initial single daily dose does not provide
n opportunity to adjust the dosage to obtain an op-
imal AUC of Bu. Thus, we hypothesized that a test
ose of IV Bu (0.8 mg/kg over 2 hours) several days
efore the 2 planned treatment doses of Bu could
rovide a PK basis for achieving an optimal AUC of
u. PK analysis of the ﬁrst treatment dose was per-
ormed to assess this hypothesis. A target AUC of
200 to 4800 mol · min was considered optimal for
he single daily dose of Bu.
K Determination of the Test and First Single
aily Dose
The collection of blood samples for PK of the test
nd single daily dose used in this RIC protocol were
ollected starting immediately before the start of the
V Bu infusion (baseline), and 15 minutes 1.0, 2.0, 2.5,
.0 for the test dose, and 3 more samples at 8.0, 12.0,
nd 24 hours after the end of the infusion. The 24.0-
our sample was drawn before the start of the next
nfusion, on day 4. Blood samples were placed on
et ice after blood collection and processed within 1
our after collection. Plasma was separated by centrif-
gation at 2500 rpm for 10 minutes at 4°C. Plasma
as split into 2 equal amounts in 2 separate cryovials,
abeled, and then stored at 20°C until the complete
et of blood samples for each dose was obtained. It was
hen shipped to the Seattle Cancer Care Alliance
linical Pharmacokinetics Laboratory (n  28). For
dministrative reasons, the PK samples (test dose and
rst therapeutic dose) were assayed at the University
f Pennsylvania pharmacology laboratory (n  2) for c
74nalysis and determination of the AUC and clearance
f IV Bu.
alculation of the AUC, Clearance, and
ose-Modification Criteria
Clearance and bioavailability were calculated from
he ﬁrst dose by ﬁtting a biexponential equation with
he RSTRIP program (MicroMath, Salt Lake City,
T) to the data [14]. The AUC was calculated by
rapezoidal approximation and extrapolation based on
omputer-generated parameters from 0 to inﬁnity.
he clearance was calculated by using the dose given
ivided by the weight and then divided by the AUC.
n the basis of these parameters of the test dose, the
ose was modiﬁed to achieve an optimal AUC for the
ingle daily-dose administration.
upportive Care
Patients underwent transplantation in the outpa-
ient setting and received immune globulin (250 mg/
g) or CytoGam (Medimmune, Gaithersburg, MD)
100 mg/kg) on day 1 and continuing each week
ntil day100 and then monthly up to 6 months after
ransplantation or until they were able to sustain their
mmunoglobulin level without support. Phenytoin
wice daily was administered for anticonvulsant pro-
hylaxis on day 1 before single IV Bu was started
ith standard dosing for 48 hours after completion of
V Bu dosing.
Fluconazole 3 to 5 mg/kg/d IV or orally, with a
aximum dose of 200 mg, was started with the con-
itioning therapy and continued until day 100. If
ystemic fungal infection was suspected or diagnosed
fter the completion of the preparative regimen, lipo-
ome amphotericin B (AmBisome, Fujisawa, Deer-
eld, IL) or voriconazole was instituted, and ﬂucon-
zole was discontinued.
For the prevention of herpes simplex virus infec-
ions, acyclovir 250mg/m2 orally or IVwas administered
very 12 hours beginning on day 5 and continuing
ntil day100. Screening for cytomegalovirus was pur-
ued with reverse transcriptase-polymerase chain reac-
ion (PCR), which was performed weekly in patients at
isk. If 1000 copies or an increasing number of
opies were detected, ganciclovir was administered at
mg/kg every 12 hours until the number of copies was
ecreasing and was then administered at 5 mg/kg daily
ntil 2 consecutive cytomegalovirus PCR assays be-
ame negative 1 week apart. To prevent Pneumocystis
arinii infection, pentamidine 4 mg/kg IV was admin-
stered on day 1 and every 30 days up to 6 months
fter transplantation or 3 months after the cessation of
mmunosuppressive therapy.
ngraftment
We evaluated posttransplantation myeloid and T-
ell chimerism weekly by using a rapid and sensitive
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Single Daily-Dose Intravenous Busulfan in Pediatric Transplant Patients
BCR method adopted at Children’s Memorial Hospi-
al. The method uses isolation of genomic DNA and
NA, synthesis of complementary DNA, PCR ampli-
cation, and DNA sequencing [15]. Donor chimerism
fter SCT was assessed with variable-number tandem
epeat analysis of the peripheral blood.
oxicities and Mortality
Regimen-related toxicities and transplant-related
ortality were recorded. Death after relapse or pro-
ressive disease was designated as due to primary dis-
ase.
tatistical Analysis
Overall survival curves were produced by using
he product-limit method of Kaplan and Meier [16].
o compare the measured AUC and the clearance
f the test dose of IV Bu with the measured AUC
nd clearance of the single daily dose, a paired t test
as used [17].
ESULTS
atient Characteristics
Thirty pediatric patients were treated between
able 2. Busulfan Toxicities and Engraftment
Patient No. Seizures VOD N&V Chimerism
1 No No Yes Not achieved
2 No No Yes 14 d
3 No No Yes 21 d
4 No No Yes Not achieved
5 No No Yes 53 d
6 No No Yes 19 d
7 No No Yes 15 d
8 No No Yes 27 d
9 No No Yes 39 d
10 No No No 21 d
11 No No No Not achieved
12 No No Yes 21 d
13 No No Yes 21 d
14 No No Yes 21 d
15 No No Yes 14 d
16 No No Yes Partial day 12 lost
graft
17 No No No 61 d
18 No No No 27 d
19 No No No 14 d
20 No No No 14 d
21 No No No 35 d
22 No No No 29 d
23 No No No Partial at 120 d
24 No No No Not achieved
25 No No Mild Partial at 42 d
26 No No No Partial at 35 d
27 No No No 21 d
28 No No No 14 d
29 No No Mild 14 d
30 No No No 14 d
&V indicates nausea and vomiting.uly 2003 and September 2005. The patients’ charac-
B&MTeristics are summarized in Table 1. The mean age
as 6.9  5.4 years (SEM, range, 0.11-16 years): 17
ale and 13 female patients were enrolled in the
tudy. The median weight was 21 kg, with a range of
.2 to 68 kg. Fourteen patients were diagnosed with
onmalignant conditions: aplastic anemia, hyper im-
unoglobulin M immunodeﬁciency, X-linked lym-
hoproliferative disease, Gaucher disease, Wiskott-
ldrich syndrome, Kostmann syndrome, Krabbe
isease, Omenn syndrome, and severe combined im-
unodeﬁciency. Sixteen had malignancies: chronic my-
logenous leukemia (CML), familial hemophagocytic
ymphohistiocytosis, acute lymphoblastic leukemia
ALL), myelodysplastic syndrome, non-Hodgkin lym-
homa, and neuroblastoma. There were 13 patients
ounger than 4 years of age.
ngraftment (Chimerism)
Twenty-one patients (70%) achieved full donor
himerism within a mean of 24.5 days after transplan-
ation (range, 14-61 days; Table 2). Partial chimerism
as noted in 2 patients (6 %) with graft loss at 12 and
60 days after initial engraftment. Four patients did
ot engraft, and 1 patient was not evaluable for en-
raftment because of an early death. In 2 patients it is
oo early to assess engraftment.
egimen-Related Toxicity
None of the pediatric patients in this study devel-
ped hepatic veno-occlusive disease (VOD) or sei-
ures. Mild to moderate nausea and vomiting were
oted in 15 (50%) of 30 patients.
Acute graft-versus-host disease (GVHD) grade I
o II was seen in 10 patients (33%), and 1 patient (3%)
eveloped grade III GVHD after receiving a single
aily-dose regimen of IV Bu Flu and ATG before
llogeneic SCT (Table 3). No GVHD was found in
he remaining evaluable patients (44%). No deaths
ere attributed to either acute or chronic GVHD.
able 3. Transplant-Related Toxicities
Variable n
rades I-II acute GVHD 9
rades III acute GVHD 1
o GVHD 20
eizures 0
OD 0
ausea and vomiting 16 (mild to moderate)
resent status of patients
Deceased due to infection 3
Deceased due to progressive
disease 4
Alive and in clinical remission 19
Alive with disease 2
Second transplantation 1
Deceased from VOD after secondtransplantation (myeloablative) 1
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4utcomes
Twenty-one (67%) of the children in the study are
live, and 19 were in clinical remission at a median of
8 months after transplantation (Figure 1). Trans-
lant-related mortality occurred in 1 patient (3%), 2
atients developed infection (adenovirus and aspergil-
osis), and 5 patients (17%) developed disease progres-
ion (Table 3). Two patients not in remission received
second transplant, and 1 patient who received a
econd transplant subsequently died from VOD. A
aplan-Meier plot of event-free survival after trans-
lantation in pediatric patients showed nearly 60%
urvival of the patients who received a test dose and a
able 4. Summary of the Results of the Pharmacokinetics of the Test
ose and the Therapeutic Single Daily Dose
Variable Data
est dose 0.8 mg/kg IV Bu
est dose administered total (mg) Mean, 20.3
Median, 18.8
SD, 15.2
Range, 3-68
learance (mL/min/kg) Mean, 3.6
Median, 3.5
SD, 1.2
Range, 2.4-7.3
UC (mol · min) Mean, 963
Median, 953
SD, 215
Range, 439-1315
ingle-dose IV Bu administered (mg/kg) 3.2 in 7 patients
>3.2 in 13 patients
<3.2 in 10 patients
ctual single IV Bu dose administered
(mg/kg) Mean, 3.4
Median, 3.2
SD, 0.93
Range, 2.5-7.2
learance (mL/min/kg) Mean, 3.6
Median, 3.5
SD, 0.97
Range, 2.5-6.9
UC (mol · min) Mean, 3740
Median, 3798
SD, 1073
0 5 10 15 20 25 30
0
20
40
60
80
100
Legend
months post transplant
%
 O
S
igure 1. Kaplan-Meier plot of overall survival (OS) of pediatric
atients.d
Range, 1511-7254
76educed-intensity single daily dose of IV Bu Flu and
n ATG conditioning regimen (Figure 1).
usulfan Pharmacokinetics
The results of the PK evaluation of a test dose of
V Bu 0.8 mg/kg are shown in Table 4. Samples from
6 patients yielded informative results. Results from 2
atients indicated incorrect timing of sample procure-
ent, and 2 patients’ samples were mishandled by the
ourier service during shipping. The total median test
ose of IV Bu administered was 18.8 mg, with a range
f 3 to 68 mg. The median clearance of Bu was 3.6
L/min/kg (range, 2.4-7.3 mL/min/kg). The median
UC reached with the test dose in 24 of 30 patients
as 953 mol · min, with a range of 439 to 1315
mol · min. Details of the PK results in 30 pediatric
atients who received a single daily dose of IV Bu are
hown in Table 4. The single daily dose of IV Bu
dministered was modiﬁed in 20 patients because of
he results of the previously administered test dose.
he scheduled dose of 3.2 mg/kg was administered to
of 30 patients, whereas lower adjusted doses ranging
rom 2.5 to 3.1 mg/kg were administered to 9 chil-
ren. Upward adjustments were made in 13 children
hat ranged from 3.3 to 7.2 mg/kg. The actual median
ose of IV Bu delivered was 3.2 mg/kg (range, 2.5 to 7.2
g/kg). Median clearance was 3.5 mL/min/kg (range,
.5-6.9 mL/min/kg). The median measured AUC was
798 mol · min (range, 1511-7254 mol · min). The
arget AUC was achieved in 23 of 30 patients; 6 of the
patients who did not attain the target AUC were
atients 2 years old.
Figure 2 shows the signiﬁcant difference (P 
001) between the AUC achieved after a single test
ose (0.8 mg/kg) of IV Bu versus a single daily dose
3.2 mg/kg) of IV Bu in pediatric patients, as expected
ith a 4-times-higher dose. As shown in Figure 3, the
est dose clearance and the single daily-dose clearance
ere almost identical with the exception of 2 patients.
ne had a high clearance after the test dose, but it was
AUC comparision between test
dose and single dose
AUC test AUC single
0
2500
5000
7500
p.0001
igure 2. Comparative AUC between IV Bu test dose and single
ose in pediatric patients.
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Breatly reduced after the single daily dose. One patient
ith a normal clearance after the test dose had a much
igher clearance after the single daily dose. Because
o concomitant drugs were given during the Bu infu-
ion, we cannot explain this discrepancy. There was no
igniﬁcant difference (P  .90) in clearance between
he test dose and single daily dose. The patient distri-
ution regarding dose modiﬁcation and the achieve-
ent of an optimal AUC is shown in (Figure 4).
ISCUSSION
The chief ﬁnding of this study was that a test dose
f IV Bu several days before the administration of a
ingle daily dose was useful to adjust the doses of the
ingle daily dose of Bu to achieve an optimal AUC in
hildren 2 years of age. Another important ﬁnding
f the study was that a regimen composed of Flu and
single daily-dose regimens (IV Bu and ATG) is a safe
nd effective conditioning drug combination in pedi-
tric patients undergoing HSCT. Successful engraft-
ent, as measured by full and mixed chimerism, oc-
urred in 26 of 30 patients in the absence of VOD and
ther severe toxicities, which were not expected with
his regimen. Favorable outcomes and low regimen-
elated toxicities in this study in children reﬂect sim-
lar outcomes in adult patients with high-risk and
ow-risk malignancies with a combination of IV Bu
nd Flu before allogeneic SCT.
One major problem using oral Bu in pediatric
atients is nonretention of the drug as a result of
omiting and variations in bioavailability because of
astrointestinal permeability or intestinal metabolism
18-20]. The interpatient bioavailability of orally ad-
inistered Bu in children varied as much as 5-fold [5],
long with a 6- to 20-fold variation in apparent clear-
nce [21-23]. An IV Bu formulation can avert these
ssues [6,24,25], although even with an IV formula-
ion, variable clearance of Bu may result in either
clearance test clearance single
0.0
2.5
5.0
7.5
p=0.99
Comparison of the clearance of the
test dose and the single dose.
m
l/
m
in
/K
g
igure 3. Comparison of the clearance of the test dose of IV Bu and
single IV dose in pediatric patients.nadequate or excessive systemic drug exposure. Such d
B&MTK and pharmacodynamic clearance possibilities with
V doses of Bu may increase the risk of graft rejection
nd disease recurrence or toxicity.
Therefore, in this study, a test dose of IV Bu was
sed in each pediatric patient before the administra-
ion of the conditioning regimens consisting of 2 sin-
le daily doses of Bu. We hypothesize that it is im-
ortant to establish Bu clearance and AUC in each
ndividual for a successful clinical outcome. An AUC
f 800 to 1200 mol · min of Bu was anticipated for
he test dose. A median AUC of 953 mol · min
range, 439-1315 mol · min) was achieved, with a
edian clearance of 3.5 mL/min/kg (range, 2.4-7.3
L/min/kg). These ﬁndings conﬁrm the results of a
revious study in which a test dose of 0.8 mg/kg
esulted in a median AUC of 1034 mol · min (range,
16-1315 mol · min) and a median clearance of 3.1
L/min/kg (range, 2.4-3.9 mL/min/kg) [26].
A test dose of IV Bu was necessary to determine
hether modiﬁcation of the single daily dose of IV Bu
as required in each patient undergoing HSCT. The
cheduled dose of 3.2 mg/kg was given only to 6
atients: the rest either had an upward or downward
djustment to achieve the desired AUC.
PK studies of IV Bu in children with malignant
nd nonmalignant conditions are limited. In one study
f 6 children undergoing allogeneic HSCT and re-
eiving IV Bu 4 times daily, systemic exposure of Bu
as adequately estimated with limited sampling (2.5
nd 4 hours). In a study of a small number of children,
ystemic exposure to IV Bu seemed to be relatively
ow in contrast to that in adults [27]. The low vari-
bility of IV Bu in children might be the result of the
ncreased clearance previously described after the ad-
inistration of oral Bu [28-30]. The total body clear-
nce of Bu was signiﬁcantly higher in young children
7.3 mL/min/kg) as compared with both older chil-
ren and adults (3.02 and 2.7 mL/min/kg, respec-
ively) [29]. A higher clearance of Bu in children than
      30 patients 
Age   <2 years (n=10)   >2 years (n=20) 
Dose
Modification  yes  no   yes  no 
Achieved
AUC          yes no yes no        yes no yes no 
        (n=4)       (n=3)   (n=1) (n=2)     (n=14) (n=1) (n=5) (n=0) 
igure 4. Patient distribution according to age, dose modiﬁcation,
nd the ability to achieve an optimal AUC. *Two of these patients
eceived the 3.2 mg/kg without results of a test dose only one
chieved the desired AUC. †Two of these patients received the 3.2
g/Kg without results of the test dose and both achieved the
esired AUC.
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4n adults after IV Bu was conﬁrmed in additional
tudies [8,31]. A signiﬁcantly higher clearance of 3.61
nd 3.79 mL/min/kg, respectively (P  .005), was
bserved in children after the ﬁrst and the last dose of
V Bu compared with adults (2.40 and 2.33 mL/min/
g, respectively) [31].
Is important to note that despite adequate test
ose PK attained, 6 patients did not achieve the target
UC, and 5 of 6 of these patients were 2 years old.
t remains a challenging question to determine the
ptimal single daily dose of IV Bu in these patients.
he recent retrospective review by Dalle et al. [32]
eported that infants receiving IV Bu on a regular
-hour schedule showed high interpatient variability.
herefore, it is important to consider careful evalua-
ion of IV Bu PK in infants 1 year of age. A larger
tudy will be necessary to explain the differences in IV
u PK in younger patients (2 years of age).
A PK study [21] showed that children with inher-
ted disorders treated with oral Bu eliminated Bu sig-
iﬁcantly faster after the ﬁrst and the last dose with
alf-lives of 1.93 and 1.71 hours, respectively, com-
ared with children with leukemia (3.16 and 2.70
ours, respectively). The excretion of Bu in children
fter IV Bu was age and weight dependent [17], as
ound in previous studies [27,31]. Drug interactions
ay also inﬂuence the parameters of Bu PK: eg, the
se of acetaminophen or itraconazole is known to
ffect liver enzymes [33].
In this study, the conditioning combination regi-
en of Flu and 2 single daily doses of IV Bu and ATG
efore SCT was found to cause mild nausea and vom-
ting and no VOD or severe mucositis. These results
re similar to ﬁndings that were reported in a previous
tudy that used IV Bu and Flu in patients 15 to 64
ears of age with hematologic malignancies [10].
ransplantation-related mortality, an indication of
cute toxicity, was relatively low, and the overall non-
elapse mortality rate indicates that a regimen of IV
u and Flu did not seem to result in any major delayed
ngraftment [10].
We have previously reported that an RIC (non-
yeloablative) regimen consisting of Flu, IV Bu  8
oses, and ATG for HSCT in children with nonma-
ignant diseases produced day 100 transplantation-
elated mortality of 15%, a 72% engraftment, and a
-year overall survival of 84%, along with minimal
hort-term toxicities and an incidence of grade II to
V acute GVHD of 8% [12]. Therefore, it seems that
n RIC regimen followed by SCT provides a good
lternative to myeloablative SCT for children with
onmalignant disorders [12,35].
The relationship between the range of AUC val-
es and toxicities with 2 single daily doses of IV Bu
dministration was conﬁrmed in this study in children.
hat is, achieving targeted Bu AUC values with IV Bu
as fundamental in the therapeutic value and in pre-
78enting the toxicities usually noted with the condi-
ioning regimen [32,34-37].
In conclusion, Flu and 2 single daily doses of Bu
nd ATG as a conditioning regimen was effective and
afe in 30 pediatric patients with malignant and non-
alignant conditions undergoing SCT. We found it
seful to use a test IV Bu dose to determine whether
t was necessary to adjust the single daily doses of IV
u. PK studies showed that the clearance of the test
ose correlated with the clearance of the therapeutic
ose. Engraftment occurred in most patients at me-
ian of 24.5 days, taking into consideration that chi-
erism studies were obtain only weekly. Toxicities
ere similar to those reported in other studies in
hildren. Additional studies are needed to determine
he therapeutic efﬁcacy of this single daily-dose ap-
roach in children undergoing SCT.
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